New drug NRM-823 takes on Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC